Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects

Neuropsychopharmacology

Volumn 32, Issue 11, 2007, Pages 2360-2368

  Malberg, Jessica E ^a,c   Platt, Brian ^a   Rizzo, Stacey J Sukoff ^a   Ring, Robert H ^a   Lucki, Irwin ^b   Schechter, Lee E ^a   Rosenzweig Lipson, Sharon ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PSYCHOGENICS INC   (United States)

Author keywords

Anxiety; Behavior; Depression; Insulin like growth factor; Mouse

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORDIAZEPOXIDE; JB1; NBI 31772; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CATECHOLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HINDLIMB SUSPENSION; INJECTIONS, INTRAVENTRICULAR; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; ISOQUINOLINES; MALE; MICE; MOTOR ACTIVITY;

EID: 34447134271     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301358     Document Type: Article

References (48)

1. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS (2000). Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci 20: 2896-2903.
2. Aberg MA, Aberg ND, Palmer TD, Alborn AM, Carlsson-Skwirut C, Bang P et al (2003). IGF-I has a direct proliferative effect in adult hippocampal progenitor cells. Mol Cell Neurosci 24: 23-40.
3. Anderson MF, Aberg MA, Nilsson M, Eriksson PS (2002). Insulinlike growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res 134: 115-122.
4. Araujo DM, Lapchak PA, Collier B, Chabot JG, Quirion R (1989). Insulin-like growth factor (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. Brain Res 484: 130-138.
5. Aron C, Simon P, Larousse C, Boissier JR (1971). Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10: 459-469.
6. Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7: 137-151.
7. Bourin M, Hascoet M, Mansouri B, Colombel MC, Bradwejn J (1992). Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci 17: 72-77.
8. Brar AK, Chernausek SD (1993). Localization of insulin-like growth factor binding protein-4 expression in the developing and adult rat brain: analysis by in situ hybridization. J Neurosci Res 35: 103-114.
9. Brunet A, Datta SR, Greenberg ME (2001). Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11: 297-305.
10. Chen C, Zhu YF, Liu XJ, Lu ZX, Xie Q, Ling N (2001). Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. J Med Chem 44: 4001-4010.
11. De Ceuninck F, Caliez A, Dassencourt L, Anract P, Renard P (2004). Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther 6: R393-R403.
12. Duman RS (2004). Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 5: 11-25.
13. Elmlinger MW, Sanatani MS, Bell M, Dannecker GE, Ranke MB (1998). Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 138: 337-343.
14. Hascoet M, Bourin M, Colombel MC, Fiocco AJ, Baker GB (2000). Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65: 339-344.
15. Hawkes C, Kar S (2003). Insulin-like growth factor-II/mannose-6-phosphate receptor: widespread distribution in neurons of the central nervous system including those expressing cholinergic phenotype. J Comp Neurol 458: 113-127.
16. Hawkes C, Jhamandas JH, Harris KH, Fu W, MacDonald RG, Kar S (2006). Single transmembrane domain insulin-like growth factor-II/mannose-6-phosphate receptor regulates central cholinergic function by activating a G-proteinsensitive, protein kinase C-dependent pathway. J Neurosci 26: 585-596.
17. Hoshaw BA, Malberg JE, Lucki I (2005). Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037: 204-208.
18. Kash SF, Tecott LH, Hodge C, Baekkeskov S (1999). Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 96: 1698-1703.
19. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602.
20. Kim B, Leventhal PS, White MF, Feldman EL (1998). Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells. Endocrinology 139: 4881-4889.
21. Kim B, van Golen CM, Feldman EL (2004). Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene 23: 130-141.
22. Kurihara S, Hakuno F, Takahashi S (2000). Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway. Endocr J 47: 739-751.
23. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A (2001). The somatomedin hypothesis: 2001. Endocr Rev 22: 53-74.
24. Liu XJ, Xie Q, Zhu YF, Chen C, Ling N (2001). Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J Biol Chem 276: 32419-32422.
25. Loddick SA, Liu XJ, Lu ZX, Liu C, Behan DP, Chalmers DC et al (1998). Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci USA 95: 1894-1898.
26. Logan A, Gonzalez AM, Hill DJ, Berry M, Gregson NA, Baird A (1994). Coordinated pattern of expression and localization of insulin-like growth factor-II (IGF-II) and IGFbinding protein-2 in the adult rat brain. Endocrinology 135: 2255-2264.
27. Mackay KB, Loddick SA, Naeve GS, Vana AM, Verge GM, Foster AC (2003). Neuroprotective effects of insulin-like growth factorbinding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab 23: 1160-1167.
28. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110.
29. Malberg JE, Schechter LE (2005). Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 11: 145-155.
30. Malberg JE, Luo B, Lin Q, Lucki I, Schechter LE, Rosenzweig-Lipson S et al (2005). Increasing insulin-like growth factor-1 (IGF-1) produces anxiolytic-like and antidepressant-like effects in rodents. Paper Presented at the Society for Neuroscience Abstracts, Washington, DC.
31. Mattson MP, Maudsley S, Martin B (2004). A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 3: 445-464.
32. McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sonksen PH (2003). Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency. Clin Endocrinol (Oxf) 59: 467-475.
33. Nagaraja TN, Patel P, Gorski M, Gorevic PD, Patlak CS, Fenstermacher JD (2005). In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res 2: 5.
34. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25.
35. Pavel ME, Lohmann T, Hahn EG, Hoffmann M (2003). Impact of growth hormone on central nervous activity, vigilance, and tiredness after short-term therapy in growth hormone-deficient adults. Horm Metab Res 35: 114-119.
36. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
37. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B et al (2006). Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 185: 218-225.
38. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE et al (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2: 590-611.
39. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994). Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology (Berl) 116: 56-64.
40. Shimasaki S, Ling N (1991). Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog in Growth Factor Res 3: 243-266.
41. Stabler B (2001). Impact of growth hormone (GH) therapy on quality of life along the lifespan of GH-treated patients. Horm Res 56(Suppl 1): 55-58.
42. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85: 367-370.
43. Stouthart PJ, Deijen JB, Roffel M, Delemarre-van de Waal HA (2003). Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinology 28: 612-626.
44. Wallymahmed ME, Baker GA, Humphris G, Dewey M, MacFarlane IA (1996). The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. Clin Endocrinol (Oxf) 44: 403-411.
45. Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P (1999). Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 68: 161-181.
46. Ye P, D'Ercole AJ (2006). Insulin-like growth factor actions during development of neural stem cells and progenitors in the central nervous system. J Neurosci Res 83: 1-6.
47. Yee D (2006). Targeting insulin-like growth factor pathways. Br J Cancer 94: 465-468.
48. Zenker S, Haverkamp F, Klingmuller D (2002). Growth hormone deficiency in pituitary disease: relationship to depression, apathy and somatic complaints. Eur J Endocrinol 147: 165-171.